News
Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback